Washington, DC: Clinical and preclinical research on the therapeutic use of cannabis indicates that cannabinoids may curb the progression of various life-threatening diseases – including multiple sclerosis, Alzheimer’s disease, and brain cancer, according to an updated report published today by the NORML Foundation.
Now in it’s third edition, NORML’s revised report, “Emerging Clinical Applications for Cannabis & Cannabinoids: A Review of the Recent Scientific Literature, 2000 – 2009,” reviews nearly 200 scientific trials assessing the therapeutic utility of cannabinoids for the treatment of nineteen clinical indications: Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS), chronic pain, diabetes mellitus, dystonia, fibromyalgia, gastrointestinal disorders, gliomas, hepatitis C, human immunodeficiency virus (HIV), hypertension, incontinence, methicillin-resistant Staphyloccus aureus (MRSA), multiple sclerosis, osteoporosis, pruritus, rheumatoid arthritis, sleep apnea, and Tourette’s syndrome.
NORML Deputy Director Paul Armentano, who authored the report, said: “The conditions profiled in this report were chosen because patients frequently ask me about the use of cannabis to treat these disorders. Ideally, with this report in their hands, patients can now begin talking openly with their physicians about whether cannabis therapy is appropriate for them.”
Full text of the report is now available online at: norml.org. Hard copies will be available for purchase shortly.
For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org.